Allogene Therapeutics (ALLO) Cash from Operations (2018 - 2026)
Allogene Therapeutics (ALLO) reported Cash from Operations of 12913000.0 for Q1 2026, up 75.6% on a YoY basis from 7353512.04 in Q1 2025, and up 53.21% sequentially from 27599000.0 in Q4 2025.
Allogene Therapeutics (ALLO) Cash from Operations (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Cash from Operations data on file, last reported at 12913000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 75.6% year-over-year to 12913000.0; the trailing twelve-month figure through Mar 2026 stood at 109230000.0 (up 44.65% YoY), and the FY2025 full-year result was 149246000.0, up 25.49% from the prior year.
- Cash from Operations rose to 12913000.0 in Q1 2026, from 27599000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 12913000.0 in Q1 2026 to a low of 68237000.0 in Q1 2022.
- A 5-year average of 48277117.65 and a median of 52929000.0 in 2025 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations slumped 45.44% in 2023 and soared 75.6% in 2026, its largest moves.
- Tracing ALLO's Cash from Operations over 5 years: stood at 62096000.0 in 2022, then increased by 13.51% to 53707000.0 in 2023, then soared by 31.67% to 36698000.0 in 2024, then climbed by 24.79% to 27599000.0 in 2025, then soared by 53.21% to 12913000.0 in 2026.
- Business Quant data shows ALLO's Cash from Operations at 12913000.0 in Q1 2026, 27599000.0 in Q4 2025, and 29688000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | -12.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.91 Mn |
| Mar 31, 2026 | -12.91 Mn |
| Dec 31, 2025 | -27.60 Mn |
| Dec 31, 2025 | -27.60 Mn |
| Sep 30, 2025 | -29.69 Mn |
| Sep 30, 2025 | -29.69 Mn |
| Jun 30, 2025 | -39.03 Mn |
| Jun 30, 2025 | -39.03 Mn |
| Mar 31, 2025 | -52.93 Mn |
| Mar 31, 2025 | -52.93 Mn |
| Dec 31, 2024 | -36.70 Mn |
| Dec 31, 2024 | -36.70 Mn |
| Sep 30, 2024 | -44.12 Mn |
| Sep 30, 2024 | -44.12 Mn |
| Jun 30, 2024 | -63.59 Mn |
| Jun 30, 2024 | -63.59 Mn |
| Mar 31, 2024 | -55.90 Mn |
| Mar 31, 2024 | -55.90 Mn |
| Dec 31, 2023 | -53.71 Mn |
| Dec 31, 2023 | -53.71 Mn |